Liver Disease

Gilead’s Livdelzi, a selective peroxisome proliferator-activated receptor delta agonist, has received accelerated FDA approval for the treatment of primary biliary cholangitis, according to a company release.

Every year on July 28th, clinicians and researchers recognize World Hepatitis Day to bring awareness to one of the world’s deadliest but preventable viruses and continue efforts to meet the global goal of eliminating viral hepatitis by 2030

Remaining current on screening for hepatocellular carcinoma correlated with a “survival benefit” in older adults with hepatitis C virus-related cirrhosis who achieved viral cure but later developed HCC, according to researchers.

In a dose-dependent manner, fazirsiran reduced serum and liver concentrations of Z-AAT and also improved histological measures in patients with homozygous ZZ alpha-1 antitrypsin deficiency-associated liver disease, according to data.

In a Healio video exclusive, Edward V. Loftus Jr., MD, noted that, despite the boom in glucagon-like peptide-1 agonists for diabetes and weight loss, its role in the treatment of liver disease is still up for debate.

Statin initiation in patients with stroke etiologies not indicated for secondary prevention with statin therapy could hypothetically cause thousands of adverse events every year, according to a new meta-analysis published in Stroke.

In a new clinical practice guideline, the ACG has provided evidence-based recommendations for the diagnosis and management of the most common focal liver lesions among individuals without known liver disease.

Cancer survivors who identify as LGBTQ+ had increased risk for numerous chronic health issues compared with non-LGBTQ+ survivors, results from a survey study showed.

In a Healio video exclusive, Anu Osinusi, MD, MPH, reported long-term bulevirtide monotherapy 2 mg and 10 mg remained safe and effective for chronic hepatitis D virus with improved biochemical, fibrosis and virologic markers at 144 weeks.

WASHINGTON — Glucagon-like peptide-1 receptor agonists significantly reduced alanine aminotransferase levels in pediatric metabolic dysfunction-associated steatotic liver disease, especially those with type 2 diabetes, researchers reported.